Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aphios has won a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4m over two years.
Subscribe to our email newsletter
The National Institute on Aging (NIA), part of the NIH, awarded the grant to develop an Alzheimer’s disease therapeutic.
Aphios will collaborate with Louisiana State University Health Sciences Center, which will conduct in vitro and in vivo efficacy, toxicity and pharmacokinetic studies in triple transgenic AD mice.
Aphios president and CEO Trevor Castor said they are developing novel formulations of APH-0703 based on Aphios’ proprietary hydrophobic-based formulation and patented SFS-PNS polymer nanospheres technologies.